Figure 2.

Combined PI3Kγ/δ blockade or GSI reduces tumor burden and prolongs the survival of mice with Lmo2-driven T-ALL. A and B, Flow cytometric analysis of disease status in CD2-Lmo2 transgenic mice immediately before and 4 days and 7 days after initiating treatment with either the dual PI3Kγ/δ inhibitor CAL-130 (A; 10 mg/kg every 8h) or the γ-secretase inhibitor DBZ (B; 10 μmol/kg daily) for 7 days. Tumor response to drug treatments was confirmed by changes in circulating blasts (Thy1.2⁺/Ki67⁺) and evidence of propidium iodide (PI)-staining. C, Kaplan-Meier survival curves for CD2-Lmo2 mice with T-ALL treated with either CAL-130 or DBZ for 7 days. The latter only included animals that received the full course of drug, P = 0.64 (log-rank test).